Experimental Alzheimer’s drug shows promising results in early studies

Researchers reported that an experimental drug targeting tau protein levels shows promise in slowing early Alzheimer’s disease progression. The study involved about 400 participants and found signs of cognitive decline reduction, with one dose achieving a 26% decrease in decline comparable to existing amyloid treatments. While the drug did not meet all primary goals, results suggest potential benefits and warrant larger studies.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل